Analysis of risk factors: The rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue 3, 2006, Pages 231-245

  Schwarz, Jiří ^a   Pytlík, Robert ^b   Doubek, Michael ^c   Brychtová, Yvona ^c   Dulíček, Patr ^d   Campr, Vít ^a,b   Křen, Leoš ^c   Penka, Miroslav ^c  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Essential thrombocythemia; Idiopathic myelofibrosis; Myeloproliferative disease; Polycythemia vera; Risk factors; Thrombosis; Treatment algorithm

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ALPHA INTERFERON; ANAGRELIDE; ANTIFIBRINOLYTIC AGENT; ANTITHROMBOCYTIC AGENT; BUSULFAN; CLOPIDOGREL; CYTOSTATIC AGENT; ETAMSYLATE; HYDROXYUREA; INDOBUFEN; MELPHALAN; NEW DRUG; PHOSPHORUS; PIPOBROMAN; TICLOPIDINE; WARFARIN;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; ARTERY THROMBOSIS; BLEEDING; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CZECH REPUBLIC; DISEASE CLASSIFICATION; DISEASE COURSE; DOSE RESPONSE; DRUG MECHANISM; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; LEUKEMOGENESIS; LOW DRUG DOSE; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYCYTHEMIA VERA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPHERESIS; THROMBOPHILIA; VEIN THROMBOSIS; WORLD HEALTH ORGANIZATION;

CHRONIC DISEASE; CZECHOSLOVAKIA; HUMANS; MYELOPROLIFERATIVE DISORDERS; PRACTICE GUIDELINES; RISK FACTORS; SOCIETIES, MEDICAL; THROMBOCYTOSIS;

EID: 33646493889     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-939434     Document Type: Review

References (125)

1. Murphy S, Peterson P, Hand H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34:29-39
2. Michiels JJ. Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia. Neth J Med 1997;51:57-64
3. Michiels JJ, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin Thromb Hemost 1997;23:339-347
4. Imbert M, Pierre R, Thiele J, Vardiman J, Brunning R, Flandrin G. Essential thrombocythemia. In: Jaffe E, Harris N, Stein H, Vardiman J, eds. WHO Classification of Tumours: Pathology & Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:39-41
5. Pierre R, Imbert M, Thiele J, Vardiman J, Brunning R, Flandrin G. Polycythemia vera. In: Jaffe E, Harris N, Stein H, Vardiman J, eds. WHO Classification of Tumours: Pathology & Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:32-34
6. Thiele J, Pierre R, Imbert M, Vardiman J, Brunning R, Flandrin G. Chronic idiopathic myelofibrosis. In: Jaffe E, Harris N, Stein H, Vardiman J, eds. WHO Classification of Tumours: Pathology & Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:35-38
7. Michiels JJ, Thiele J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol 2002;76:133-145
8. Michiels JJ. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia. Hematol J 2004;5:93-102
9. Michiels JJ, Kvasnicka HM, Thiele J. Myeloproliferative disorders. Current Perspectives on Diagnostic Criteria, Histopathology and Treatment in Essential Thrombocythemia, Polycythemia Rubra Vera and Chronic Idiopathic Myelofibrosis. Much, Germany:; 2005
10. Thiele J, Kvasnicka HM, Werden C, Zankovich R, Diehl V, Fischer R. Idiopathic primary osteo-myelofibrosis: a clinicopathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. Leuk Lymphoma 1996;22:303-317
11. Thiele J, Kvasnicka HM, Diehl V, Fischer R, Michiels JJ. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leuk Lymphoma 1999;33:207-218
12. Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 2003;82:148-152
13. Schwarz J. Essential thrombocythemia: the experience with anagrelide and its place in the treatment algorithm. [In Czech] (abst). In: XIIIth Czech and Slovak Hematological and Transfusiological Congress. Prague, Czech Republic 2002:P/154
14. Penka M, Buliková A, Matýšková M, Zavřelová J, Doubek M. Efficacy of anagrelide in the treatment of essential thrombocythemia [In Czech]. (abst). In: XIIIth Czech and Slovak Hematological and Transfusiological Congress. Prague, Czech Republic; 2002:P/155
15. Penka M, Schwarz J, Pytlík R, Doubek M, Brychtová Y, Dulíček P. Practice guidelines for diagnosis and therapy of essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases [In Czech]. Vnitr Lek 2005;51:741-751
16. Schwarz J, Penka M. Thrombocytosis and thrombocythemia. [In Czech]Vnitr Lek 2005;51:861-871
17. Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol 1975;12:339-351
18. Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 1999; 36:9-13
19. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999;17:2954-2970
20. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. The value of bone marrow histology in differentiating between early stage polycythemia vera and secondary (reactive) polycythemias. Haematologica 2001;86:368-374
21. Thiele J, Kvasnicka HM, Orazi A. Bone marrow histopathology in myeloproliferative disorders-current diagnostic approach. Semin Hematol 2005;42:184-195
22. Georgii A, Buhr T, Buesche G, Kreft A, Choritz H. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leuk Lymphoma 1996;22(suppl 1):15-29
23. Harrison CN. Essential thrombocythaemia: challenges and evidence-based management. Br J Haematol 2005;130:153-165
24. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Early-stage idiopathic (primary) myelofibrosis-current issues of diagnostic features. Leuk Lymphoma 2002;43:1035-1041
25. Buhr T, Georgii A, Choritz H. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. Pathol Res Pract 1993;189:121-132
26. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. Haematologica 2000;85:1126-1134
27. Thiele J, Kvasnicka HM, Schmitt-Graeff A, Diehl V. Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients. Leuk Lymphoma 2003;44:949-953
28. Thiele J, Kvasnicka HM, Schmitt-Graeff A, Zankovich R, Diehl V. Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients. Am J Hematol 2002;70:283-291
29. Bellucci S, Janvier M, Tobelem G, et al. Essential thrombocythemias. Clinical evolutionary and biological data. Cancer 1986;58:2440-2447
30. Hehlmann R, Jahn M, Baumann B, Kopeke W. Essential thrombocythemia. Clinical characteristics and course of 61 cases. Cancer 1988;61:2487-2496
31. Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990;66:549-556
32. van Genderen PJJ, Mulder PGH, Waleboer M, van de Moesdijk D, Michiels JJ. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol 1997;97:179-184
33. Michiels JJ. Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. Clin Appl Thromb Hemost 1999;5:30-36
34. Bazzan M, Tamponi G, Schinco P, et al. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Ann Hematol 1999;78:539-543
35. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117:755-761
36. Michiels JJ, Kutti J, Stark P, et al. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis. Neth J Med 1999;54:46-62
37. Thiele J, Kvasnicka HM, Schmitt-Graeff A, Diehl V. Bone marrow histopathology following cytoreductive therapy in chronic idiopathic myelofibrosis. Histopathology 2003;43:470-479
38. Thiele J, Kvasnicka HM, Fuchs N, Brunnbauer K, Volkwein N, Schmitt-Graeff A. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. An immunohistochemical and morphometric study of sequential trephine biopsies. Haematologica 2003;88:1130-1138
39. Mitus AJ, Schafer AI. Thrombocytosis and thrombocythemia. Hematol Oncol Clin North Am 1990;4:157-178
40. Dawson AA, Ogston D. The influence of the platelet count on the incidence of thrombotic and haemorrhagic complications in polycythaemia vera. Postgrad Med J 1970;46:76-78
41. Barbui T, Cortelazzo S, Viero P, Bassan R, Dini E, Semeraro N. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function. Eur J Cancer Clin Oncol 1983;19:1593-1599
42. Griesshammer M, Bangerter M, van Vliet HHDM, Michiels JJ. Aspirin in essential thrombocythemia: status quo and quo vadis. Semin Thromb Hemost 1997;23:371-377
43. Michiels JJ. Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts. Pathol Biol (Paris) 2003;51:167-175
44. Michiels JJ, Berneman ZN, Schroyens W, Van Vliet HHDM. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Platelets 2004;15:67-84
45. Schwarz J, Hrachovinova I, Vorlova Z, Salaj P. Thromboembolism in thrombocythemia patients with an additional thrombophilic state, (abst 974). Hematol J 2004;5(suppl 2):S321
46. Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol 1997;56:168-172
47. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001;97:863-866
48. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990;8:556-562
49. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-1136
50. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350:114-124
51. Wehmeier A, Sudhoff T, Meierkord F. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders. Semin Thromb Hemost 1997; 23:391-402
52. Rao AK. Molecular and biochemical basis for the platelet dysfunction in myeloproliferative disorders. Semin Hematol 2004;41(suppl 3):6-9
53. Tatewaki W, Shibata A. Acquired von Willebrand disease in patients with chronic myeloproliferative disorders. Leuk Lymphoma 1989;1:51-57
54. van Genderen PJJ, Michiels JJ, van der Poel-van de Luytgaarde SCPAM, van Vliet HHDM. Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count. Ann Hematol 1994;69:81-84
55. van Genderen PJJ, Budde U, Michiels JJ, van Strik R, van Vliet HHDM. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br J Haematol 1996;93:962-965
56. Michiels JJ. Aspirin and platelet-lowering agents for the prevention of vascular complications in essential thrombocythemia. Clin Appl Thromb Hemost 1999;5:247-251
57. Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 1999; 13:150-154
58. Randi ML, Fabris F, Rossi C, Tison T, Barbone E, Girolami A. Sex and age as prognostic factors in essential thrombocythemia. Haematologica 1992;77:402-404
59. Conlan MG, Haire WD. Low protein S in essential thrombocythemia with thrombosis. Am J Hematol 1989; 32:88-93
60. Bucalossi A, Marotta G, Bigazzi C, Galieni P, Dispensa E. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Am J Hematol 1996;52:14-20
61. Amitrano L, Guardascione MA, Ames PR, et al. Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease. Am J Hematol 2003;72:75-81
62. Ruggeri M, Gisslinger H, Tosetto A, et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 2002;71:1-6
63. Gisslinger H, Mannhalter C, Pabinger I, et al. High risk of deep vein thrombosis in carriers of a prothrombin-gene mutation in patients with polycythemia vera and essential thrombocythemia. (abst 3144). Blood 2002;100:796
64. Kessler CM. Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders. Semin Hematol 2004;41 (suppl 3):10-14
65. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004;89:215-232
66. Harrison CN, Donohoe S, Carr P, Dave M, Mackie I, Machin SJ. Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which maybe associated with thrombosis. Thromb Haemost 2002;87:802-807
67. Musolino C, Alonci A, Bellomo G, et al. Myeloproliferative disease: markers of endothelial and platelet status in patients with essential thrombocythemia and polycythemia vera. Hematology 2000;4:397-402
68. Musolino C, Calabro L, Bellomo G, et al. Soluble angiogenic factors: implications for chronic myeloproliferative disorders. Am J Hematol 2002;69:159-163
69. Teofili L, Pierconti F, Di Febo A, et al. The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia. Blood 2002;100:714-717
70. Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999;93:417-424
71. Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131:208-213
72. Gisslinger H, Rodeghiero F, Ruggeri M, et al. Homocysteine levels in polycythaemia vera and essential thrombocythaemia. Br J Haematol 1999;105:551-555
73. Griesshammer M, Grünewald M, Michiels JJ. Acquired thrombophilia in pregnancy: essential thrombocythemia. Semin Thromb Hemost 2003;29:205-212
74. Ruggeri Z, Cannata ML, Stella NC, Corrado F. Pregnancy in essential thrombocythemia during aspirin treatment. Arch Gynecol Obstet 2003;268:209-210
75. Schafer AI, Levine MN, Konkle BA, Kearon C. Thrombotic disorders: diagnosis and treatment. Hematology (Am Soc Hematol Educ Program) 2005;:520-539
76. Falanga A. Thrombosis and malignancy: an underestimated problem. Haematologica 2003;88:607-610
77. Freytes CO. Thromboembolic complications related to indwelling central venous catheters in children: a neglected aspect of the study of vascular access devices. Opin Top Supp Care Oncol 2002;42:7-8
78. Tripodi A. Levels of coagulation factors and venous thromboembolism. Haematologica 2003;88:705-711
79. Nowak-Göttl U, Kosch A, Schlegel N, Salem M, Manco-Johnson M. Thromboembolism in children. Curr Opin Hematol 2002;9:448-453
80. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45
81. Chistolini A, Mazzucconi MG, Ferrari A, et al. Essential thrombocythemia: a retrospective study on the clinical course of 100 patients. Haematologica 1990;75:537-540
82. Balan KK, Critchley M. Outcome of 259 patients with primary proliferative polycythaemia (PPP) and idiopathic thrombocythaemia (IT) treated in a regional nuclear medicine department with phosphorus-32 - a 15 year review. Br J Radiol 1997;70:1169-1173
83. Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol 1991;85:124-127
84. Okamura T, Kinukawa N, Niho Y, Mizoguchi H. Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients. Int J Hematol 2001;73:194-198
85. Pettit JE. The non-leukaemic myeloproliferative disorders. In: Hoffbrand AV, Lewis SM, eds. Postgraduate Haematology. 2nd ed. London: Heinemann; 1981:577-604
86. Najean Y, Rain J-D. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997;90:3370-3377
87. Fruchtman SM. Treatment paradigms in the management of myeloproliferative disorders. Semin Hematol 2004;41(suppl 3):18-22
88. Briere J, Guilmin F. Management of patients with essential thrombocythemia: current concepts and perspectives. Pathol Biol (Paris) 2001;49:178-183
89. Barbui T. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? Semin Hematol 2004;41(suppl 3):15-17
90. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992;19(suppl 9):1-10
91. Hong Y, Erusalimsky JD. Comparison of the pharmacological mechanisms involved in the platelet lowering actions of anagrelide and hydroxyurea: a review. Platelets 2002;13:381-386
92. Raposa T, Várkonyi J. The relationship between sister chromatid exchange induction and leukemogenicity of different cytostatics. Cancer Detect Prev 1987;10:141-151
93. Mehnert K, Vogel W, Benz R, Speit G. Different effects of mutagens on sister chromatid exchange induction in three Chinese hamster cell lines. Environ Mutagen 1984;6:573-583
94. Schroeder AL. Chromosome instability in mutagen sensitive mutants of Neurospora. Curr Genet 1986;10:381-387
95. Seino Y, Nagao M, Yahagi T, Hoshi A, Kawachi T, Sugimura T. Mutagenicity of several classes of antitumor agents to Salmonella typhimurium TA98, TA100, and TA92. Cancer Res 1978;38:2148-2156
96. Marsteinstredet U, Brunborg G, Bjoras M, et al. DNA damage induced by 3-chloro-4-(dichloromethyl)-5-hydroxy-2[5H]-furanone (MX) in HL-60 cells and purified DNA in vitro. Mutat Res 1997;390:171-178
97. Andersson M, Agurell E, Vaghef H, Bolcsfoldi G, Hellman B. Extended-term cultures of human T-lymphocytes and the comet assay: a useful combination when testing for genotoxicity in vitro? Mutat Res 2003;540:43-55
98. Ficsor G, Ginsberg LC. The effect of hydroxyurea and mitomycin C on sperm motility in mice. Mutat Res 1980;70:383-387
99. Nand S, Messmore H, Fisher SG, Bird ML, Schulz W, Fisher RI. Leukemic transformation in polycythemia vera: analysis of risk factors. Am J Hematol 1990;34:32-36
100. Weinfeld A, Swolin B, Westin J. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol 1994;52:134-139
101. Randi ML, Fabris F, Girolami A. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia. Leuk Lymphoma 2000;37:379-385
102. Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol 2003;74:26-31
103. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998;91:616-622
104. Tóthová E, Fričová M, Štecová N, et al. Leukemic transformation of polycythemia vera after treatment with hydroxyurea with abnormalities of chromosome 17. Neoplasma 2001;48:389-392
105. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005;105:2664-2670
106. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005;23:2224-2232
107. Finazzi G, Barbui T. Efficacy and safety of hydroxyurea in patients with essential thrombocythemia. Pathol Biol (Paris) 2001;49:167-169
108. Barbui T. Indications for lowering platelet numbers in essential thrombocythemia. Semin Hematol 2003;40:22-25
109. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000;96:4261-4266
110. Falanga A, Marchetti M, Barbui T, Smith CW. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils. Semin Hematol 2005;42:239-247
111. Lofvenberg E, Nordenson I, Wahlin A. Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease. Cancer Genet Cytogenet 1990;49:57-67
112. Lengfelder E, Griesshammer M, Hehlmann R. Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma 1996;22(suppl 1):135-142
113. Alvarado Y, Cortes J, Verstovsek S, et al. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol 2003;51:81-86
114. Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992;92:69-76
115. Petrides PE. Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia. Expert Opin Pharmacother 2004;5:1781-1798
116. Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 1997;34:51-54
117. Gisslinger H. Management of essential thrombocythemia. Hematology (Am Soc Hematol Educ Program) 2005;1:105-110
118. Tefferi A, Barbui T. bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment. Mayo Clin Proc 2005;80:1220-1232
119. Finazzi G, Harrison C. Essential thrombocythemia. Semin Hematol 2005;42:230-238
120. Barbui T, Finazzi G. When and how to treat essential thrombocythemia. N Engl J Med 2005;353:85-86
121. Thiele J, Kvasnicka HM, Schmitt-Gräff A, Hülsemann R, Diehl V. Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis. Histol Histopathol 2004; 19:239-250
122. Steurer M, Gastl G, Jedrzejczak WW, et al. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 2004;101:2239-2246
123. Zweegman S, de Groot MR, Sonneveld P. The HOVON 58 study: pegylated interferon-2A or anagrelide in high risk essential thrombocythemia: a randomized phase II trial. Observational study of low and intermediate risk patients. Rotterdam, The Netherlands: European Working Group on Myeloproliferative Disorders 2004:79-80
124. Gilbert HS. The role of anagrelide, hydroxyurea, and interferon-α in treating the thrombocythemia of myeloproliferative disease: a new approach for the millennium. Presented at: the XVth Meeting of the International Society of Haematology, African & European Division, Durban, South Africa; September 18-23, 1999:141-143
125. Marchioli R, Finazzi G, Marfisi RM, Tognoni G, Barbui T. Clinical trials in myeloproliferative disorders: looking forward. Semin Hematol 2005;42:259-265